Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

to treat pre-cancerous cervical dysplasias and cancers caused by human papillomavirus (HPV) types 16 and 18. All dose groups developed significant antibody and T-cell immune responses; notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. VGX-3100 delivered using Inovio's proprietary CELLECTRA® intramuscular electroporation delivery device was generally safe and well tolerated at all dose levels. There were no vaccine-related serious adverse events; reported adverse events and injection site reactions were mild to moderate and required no treatment.

Subsequent to year end, Inovio initiated a Phase II clinical trial for VGX-3100. The study will assess adult females with CIN 2/3 or CIN 3, the pre-cancerous stages of abnormal cells that precede cervical cancer, and biopsy-proven HPV 16 or 18, which are responsible for 70% of CIN 2/3 and cervical cancer incidences. The randomized, placebo-controlled, double-blind study will evaluate cervical tissue changes after three 6 mg doses of VGX-3100 are administered by injection in combination with Inovio's CELLECTRA® electroporation delivery device. The company expects that a total of 148 patients will be enrolled in 25 study centers in the U.S., South Korea, South Africa, Australia, and Canada.

During 2010, Inovio observed in an interim analysis high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX™-B, a DNA vaccine for the prevention of HIV infection.

A Phase I study, called RV262, began to evaluate a unique prime-boost preventive HIV vaccination strategy aimed at global coverage. The prime is Inovio's plasmid DNA vaccine, PENNVAXTM-G. The NIAID, part of the U.S. National Institutes of Health (NIH), is sponsoring th
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... N.J., May 26, 2011 Johnson & Johnson (NYSE: ... its Pharmaceuticals business at a meeting with the investment ... and pharmaceuticals segment will review how the business plans ... needs and outpace pharmaceutical market growth with an optimized ...
... Pharmaceuticals, Inc. (NASDAQ: AMLN ) ("Amylin" or "the ... the Southern District of California issued a temporary restraining order ... ) ("Lilly") relating to its litigation with respect to the ... District Court restrained Lilly from proceeding with its plans to ...
Cached Medicine Technology:Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 2Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 3Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 4
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... N.C. New findings from the nation,s largest study ... disease on the rise among every racial and ethnic ... of Diabetes Care provide a comprehensive picture ... and racial groups in the United States, including non-Hispanic ...
... Feb. 27 Stereotaxis, Inc. (Nasdaq: ... and Drug Administration approved for marketing the NAVISTAR(R) RMT ... a Johnson & Johnson company. The NAVISTAR(R) RMT THERMOCOOL(R) ... System for mapping and radiofrequency (RF) ablation to treat ...
... a world-leading developer and marketer of innovative medical ... that it has completed the divestiture of the ... Surgical Products Holding, Inc. Aspen is a ... private equity firm focused exclusively on the healthcare ...
... Directors of Schering-Plough Corporation (NYSE: SGP ) today ... Payment will be made on May 26, 2009, to ... 1, 2009. As of Jan. 31, 2009, there were ... declared a quarterly dividend of $3.75 per share on the ...
... Study Not Atkins DietDENVER, Feb. 27 A ... titled "Comparison of Weight-Loss Diets with Different Compositions ... concluded that reduced-calorie diets result in clinically meaningful ... and carbohydrates) they emphasize. Atkins Nutritionals, Inc. ...
... Stability of Long Term Care Workforce Put at Risk by ... of LTC Sector to U.S. Economy, Jobs Base, Tax RevenueWASHINGTON, ... showing the nation,s long term care sector is a key ... tax revenue, state and national long term care leaders expressed ...
Cached Medicine News:Health News:Many faces of diabetes in American youth: The SEARCH for diabetes in youth study 2Health News:Many faces of diabetes in American youth: The SEARCH for diabetes in youth study 3Health News:Many faces of diabetes in American youth: The SEARCH for diabetes in youth study 4Health News:Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter 2Health News:ConvaTec Announces Divestiture of Unomedical Wound Care and Ophthalmics Business 2Health News:Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results 2Health News:Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results 3Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 2Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 3
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Rotating 360 degrees, 3 mm x 7 mm bite....
Right side cutting....
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches....
Medicine Products: